Management of Iliopsoas Abscess
The optimal management of iliopsoas abscess requires percutaneous catheter drainage combined with appropriate antibiotic therapy as the first-line treatment approach. 1, 2
Diagnostic Approach
- CT scan with IV contrast is the imaging modality of choice for diagnosis 1
- MRI can be used as an alternative when CT is contraindicated
- Obtain cultures during drainage to guide antibiotic therapy
Treatment Algorithm
1. Source Control
2. Antimicrobial Therapy
For immunocompetent, non-critically ill patients:
- Amoxicillin/Clavulanate 2 g/0.2 g q8h 1
- For beta-lactam allergy: Eravacycline 1 mg/kg q12h or Tigecycline 100 mg loading dose then 50 mg q12h 1
For immunocompromised or critically ill patients:
- Piperacillin/tazobactam 6 g/0.75 g loading dose then 4 g/0.5 g q6h or 16 g/2 g by continuous infusion 1
- For beta-lactam allergy: Eravacycline 1 mg/kg q12h 1
For suspected MRSA (common in primary iliopsoas abscess):
Duration of antibiotic therapy:
- 4 days in immunocompetent patients if source control is adequate 1
- Up to 7 days in immunocompromised or critically ill patients 1
- Extended therapy may be required for inadequate drainage or persistent symptoms 4
3. Surgical Intervention
- Indicated when PCD fails or is not feasible 2
- Consider early surgical intervention for:
Special Considerations
Based on Etiology
Primary iliopsoas abscess (no identifiable source):
Secondary iliopsoas abscess (from adjacent structures):
Monitoring and Follow-up
- Regular clinical assessment for resolution of fever and pain
- Follow-up imaging before catheter removal to ensure complete drainage 7
- Patients with ongoing signs of infection beyond 7 days warrant diagnostic re-evaluation 1
- Evaluate for underlying conditions in recurrent cases, particularly undiagnosed diabetes mellitus 4
Pitfalls to Avoid
- Removing drainage catheters without confirming resolution on imaging (associated with recurrence) 7
- Failing to identify and address the underlying cause in secondary abscesses
- Inadequate antibiotic coverage for likely pathogens (S. aureus for primary, enteric flora for secondary)
- Delaying surgical intervention when PCD fails, especially with gastrointestinal sources 2